Boston Scientific Corp. (BSX): Price and Financial Metrics
BSX Price/Volume Stats
Current price | $67.24 | 52-week high | $68.07 |
Prev. close | $66.23 | 52-week low | $47.51 |
Day low | $66.16 | Volume | 5,833,600 |
Day high | $67.43 | Avg. volume | 6,852,289 |
50-day MA | $64.12 | Dividend yield | N/A |
200-day MA | $55.77 | Market Cap | 100.86B |
BSX Stock Price Chart Interactive Chart >
BSX POWR Grades
- BSX scores best on the Growth dimension, with a Growth rank ahead of 98.45% of US stocks.
- The strongest trend for BSX is in Quality, which has been heading up over the past 26 weeks.
- BSX ranks lowest in Momentum; there it ranks in the 24th percentile.
BSX Stock Summary
- With a market capitalization of $84,383,007,955, BOSTON SCIENTIFIC CORP has a greater market value than 97.05% of US stocks.
- BSX's current price/earnings ratio is 70.79, which is higher than 91.05% of US stocks with positive earnings.
- In terms of volatility of its share price, BSX is more volatile than merely 1.09% of stocks we're observing.
- Stocks that are quantitatively similar to BSX, based on their financial statements, market capitalization, and price volatility, are ZTS, BDX, SYK, ETN, and IDXX.
- Visit BSX's SEC page to see the company's official filings. To visit the company's web site, go to www.bostonscientific.com.
BSX Valuation Summary
- In comparison to the median Healthcare stock, BSX's price/sales ratio is 181.82% higher, now standing at 6.2.
- Over the past 243 months, BSX's price/earnings ratio has gone up 4.1.
Below are key valuation metrics over time for BSX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BSX | 2023-12-29 | 6.2 | 4.5 | 71.0 | 43.3 |
BSX | 2023-12-28 | 6.0 | 4.4 | 69.2 | 42.3 |
BSX | 2023-12-27 | 6.0 | 4.3 | 68.8 | 42.1 |
BSX | 2023-12-26 | 6.0 | 4.3 | 68.8 | 42.1 |
BSX | 2023-12-22 | 6.0 | 4.3 | 68.7 | 42.0 |
BSX | 2023-12-21 | 5.9 | 4.3 | 68.4 | 41.8 |
BSX Growth Metrics
- Its 5 year net income to common stockholders growth rate is now at 885.52%.
- Its year over year cash and equivalents growth rate is now at -83.88%.
- The year over year net income to common stockholders growth rate now stands at 275.12%.
The table below shows BSX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 12,682 | 1,526 | 642 |
2022-09-30 | 12,567 | 1,197 | 597 |
2022-06-30 | 12,329 | 1,192 | 828 |
2022-03-31 | 12,162 | 1,528 | 754 |
2021-12-31 | 11,888 | 1,870 | 985 |
2021-09-30 | 11,470 | 2,065 | 1,100 |
BSX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BSX has a Quality Grade of C, ranking ahead of 73.14% of graded US stocks.
- BSX's asset turnover comes in at 0.362 -- ranking 120th of 186 Medical Equipment stocks.
- INGN, ECIA, and ATRC are the stocks whose asset turnover ratios are most correlated with BSX.
The table below shows BSX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.362 | 0.669 | 0.051 |
2021-03-31 | 0.328 | 0.649 | 0.032 |
2020-12-31 | 0.324 | 0.650 | 0.015 |
2020-09-30 | 0.331 | 0.672 | 0.003 |
2020-06-30 | 0.344 | 0.682 | 0.022 |
2020-03-31 | 0.386 | 0.704 | 0.043 |
BSX Price Target
For more insight on analysts targets of BSX, see our BSX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $51.08 | Average Broker Recommendation | 1.4 (Moderate Buy) |
Boston Scientific Corp. (BSX) Company Bio
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. (Source:Wikipedia)
Latest BSX News From Around the Web
Below are the latest news stories about BOSTON SCIENTIFIC CORP that investors may wish to consider to help them evaluate BSX as an investment opportunity.
Boston Sci sees Farapulse PFA receiving FDA approval in Q1More on Boston Scientific |
Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial FibrillationBoston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent atrial fibrillation (AF), the only trial to study the use of PFA as frontline therapy in patients with this form of AF. Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to ou |
3 Medical-Device Stocks Could Click in 2024Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales. |
Show Me The Money: Inside Ken Griffin's Citadel's Jaw-Dropping $7 Billion ReturnCitadel Founder and CEO Ken Griffin is one of the most successful investors of all time, managing over $62 billion in assets. He is also the founder of Citadel Securities, the largest market-making firm for the New York Stock Exchange and one of the largest designated market makers in the world. Citadel Securities is involved in one out of four stock trades placed in U.S. exchanges and nearly 40% of all retail trades. With a net worth of $37.5 billion, Griffin is one of the richest hedge fund ma |
Insider Sell Alert: EVP Wendy Carruthers Sells 11,672 Shares of Boston Scientific Corp (BSX)Boston Scientific Corp (NYSE:BSX), a leading innovator in medical solutions that improve the health of patients around the world, has recently witnessed a significant insider sell by one of its top executives. |
BSX Price Returns
1-mo | 2.16% |
3-mo | 22.30% |
6-mo | 24.59% |
1-year | 37.70% |
3-year | 76.16% |
5-year | 76.25% |
YTD | 16.31% |
2023 | 24.94% |
2022 | 8.92% |
2021 | 18.16% |
2020 | -20.50% |
2019 | 27.96% |
Continue Researching BSX
Want to see what other sources are saying about Boston Scientific Corp's financials and stock price? Try the links below:Boston Scientific Corp (BSX) Stock Price | Nasdaq
Boston Scientific Corp (BSX) Stock Quote, History and News - Yahoo Finance
Boston Scientific Corp (BSX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...